-
WM-8014: KAT6A Inhibitor Workflow Guide
2026-08-26
WM-8014 offers a reversible, competitive way to interrogate KAT6A/B-dependent chromatin regulation without relying exclusively on genetic depletion. This guide translates its selectivity profile and the RESTRICT-seq findings into practical cell-cycle, senescence, resistance, and tumor-growth workflows, with safeguards against solubility, timing, and interpretation errors.
-
PPP2R2A Loss Sensitizes HGSOC to CHK1 Inhibition
2026-08-26
The 2024 Theranostics study identifies low PPP2R2A, which encodes the PP2A B55α regulatory subunit, as a potential biomarker for sensitivity to CHK1 inhibition in high-grade serous ovarian cancer. Its experiments connect PPP2R2A loss with c-Myc-driven replication stress, increased replication initiation, and CHK1 dependence, including in models resistant to PARP inhibition.
-
miR-1268a, CD36, and Angiotensin II Heart Failure
2026-08-25
This 2024 study identifies miR-1268a as an inducible regulator of fatty-acid uptake, ATP production, and oxidative stress in Angiotensin II-treated AC16 cardiomyocytes. Its key contribution is linking miR-1268a to CD36, while also showing that miR-1268a inhibition partially reverses several cellular features of the in vitro heart-failure model.
-
Pazopanib (GW-786034): RTK Mechanism & Research
2026-08-24
Pazopanib (GW-786034) is a multi-targeted receptor tyrosine kinase inhibitor that suppresses VEGFR, PDGFR, and FGFR signaling in cancer research models. Its strongest experimental value is mechanistic: it connects angiogenesis inhibition with receptor-dependent tumor growth suppression and ATRX-stratified glioma sensitivity.
-
CFDA SE Cell Tracer Kit: Practical Protocol
2026-08-24
The CFDA SE Cell Tracer Kit provides a persistent fluorescent label for cell proliferation studies, cell lineage tracing, and related in vitro or in vivo tracking workflows. It is intended for stable covalent marking over several days, not reversible labeling, short-lived assays, or real-time monitoring that requires dye replenishment.
-
Prochlorperazine: From D2 Blockade to Assay Design
2026-08-23
Prochlorperazine is a dopamine D2 receptor antagonist with applications spanning antiemetic therapy, melanoma research, and antiviral investigation. This article presents an assay-first framework for separating receptor effects, membrane-entry phenotypes, and melanoma-specific responses.
-
Rucaparib (AG-014699) for DNA Repair Assays
2026-08-22
Rucaparib (AG-014699) enables controlled studies of PARP1 inhibition, persistent DNA damage, and radiosensitization across prostate cancer and hepatocellular carcinoma models. This practical guide connects spliceosome biology with assay design, dosing, readouts, transporter effects, and troubleshooting.
-
Angiotensin II Workflows for Vascular Research
2026-08-21
Build reproducible cell and animal models of vasoconstriction, hypertension, remodeling, and vascular smooth muscle cell hypertrophy with a sequence-defined endogenous peptide. This guide connects short exposure assays with telemetry-based chronic infusion studies and provides practical controls for sex-dependent response variability.
-
IWP-2: A Cell-Aware Wnt Assay Strategy
2026-08-20
IWP-2 is a potent Wnt production inhibitor for dissecting PORCN-dependent Wnt/β-catenin biology. This article connects its cancer research applications with a cell-aware assay framework inspired by large-scale single-nucleus profiling of atrial fibrillation.
-
SU5416: From VEGFR2 Tool to Model Variable
2026-08-20
SU5416 (Semaxanib) is more than a selective VEGFR2 inhibitor: its biological effect depends strongly on vascular context and species. This evidence-led guide explains how to use it for angiogenesis assays while avoiding misleading conclusions from pulmonary vascular models.
-
RNase R (20 U/μL) for Circular RNA Enrichment
2026-08-19
Ribonuclease R is a processive 3′-to-5′ exoribonuclease used to reduce linear RNA and enrich intact circular RNA for downstream analysis. RNase R (20 U/μL), SKU K3061, is supplied with 10× RNase R Reaction Buffer and supports RNA structure analysis, RNA stability studies, and RNA metabolism workflows.
-
Losartan and AT1R Trafficking in Diabetic Nephropathy
2026-08-19
Losartan is more than an angiotensin II receptor antagonist for blood-pressure models: it can help resolve how AT1R signaling and receptor trafficking shape renal matrix biology. This article translates recent GPR107–AT1R findings into practical assay decisions for hypertension research and cardiovascular physiology study design.
-
3X FLAG Peptide for VPS13A–XK Studies
2026-08-18
The 3X (DYKDDDDK) Peptide provides a practical detection and purification handle for recombinant protein studies. This article connects FLAG-tag workflow design with the VPS13A–XK lipid-transfer mechanism while clarifying assay opportunities, metal-related controls, and experimental limitations.
-
HDV Genotype Responses to Interferon-Alpha
2026-08-18
The reference study distinguishes how HDV genotype, cellular state, interferon-alpha subtype, and ADAR1 isoform influence antiviral activity. Its findings suggest that interferon-based treatment should account for both viral spread strategy and host-cell context, while selected interferon subtypes may be useful partners for bulevirtide.
-
SFRP1, Wnt/β-Catenin, and Oral Fibrosis
2026-08-17
A 2024 study used an arecoline-induced mouse model and complementary cell experiments to show that SFRP1 reduces neutrophil infiltration and oral submucous fibrosis while suppressing Wnt/β-catenin signaling. The work links immune-cell recruitment with fibrotic pathway activity and provides a mechanistic framework for evaluating pathway-directed interventions in oral fibrosis.